Getting Started10 min readDecember 13, 2025

    Buy Semaglutide in Memphis — $99/Month | Trimi Health

    GLP-1 weight loss treatment in Memphis — shipped directly to your Memphis address in 2–3 business days. No clinic visits, no insurance required, just $99/month for compounded semaglutide.

    Why Memphis Residents Choose Telehealth for GLP-1

    Memphis is a major metropolitan area with a population of approximately ~630,000 city / ~1.3 million metro. Despite access to quality healthcare facilities, affordable GLP-1 weight loss medications remain out of reach for many Memphis residents. Local weight loss clinics typically charge $300–600 per month for compounded semaglutide programs, and brand-name Wegovy costs $1,000–$1,400 per month without insurance.

    With an adult obesity rate of approximately 34%, Memphis faces significant public health challenges related to weight management. Many neighborhoods lack convenient access to specialized weight loss clinics, making telehealth an increasingly popular alternative for Memphis residents seeking GLP-1 treatment.

    Memphis GLP-1 Snapshot

    Population: ~630,000 city / ~1.3 million metro. Adult obesity rate: ~34%. Typical clinic cost: $300–600/mo. Brand Wegovy: $1,000–$1,400/mo. Trimi telehealth: $99/mo semaglutide, $125/mo tirzepatide.

    Learn more about how telehealth prescribing works. You can also read about Ozempic vs. Wegovy or explore our GLP-1 beginner guide.

    Memphis Pricing: Trimi vs Local Providers & Pharmacies

    OptionMonthly CostIn-Person VisitInsurance Required
    Memphis Weight Loss Clinic (avg)$300–600YesSometimes
    Memphis Pharmacy (brand Wegovy)$1,000–$1,400YesRecommended
    Trimi Telehealth (compounded)$99/mo (sema) / $125/mo (tirz)NoNo

    Read our semaglutide vs. tirzepatide comparison to understand which medication may be right for you.

    How It Works: 3 Steps to Get Semaglutide in Memphis

    Step 1: Online Health Intake

    Complete a health questionnaire covering your medical history, medications, BMI, and weight loss goals — from anywhere in Memphis.

    Step 2: Provider Review & Prescription

    A licensed provider evaluates your submission, confirms GLP-1 candidacy, and sends your prescription to a licensed compounding pharmacy.

    Step 3: Delivered to Your Memphis Door

    Temperature-controlled packaging arrives at your Memphis address within 3–5 business days. Monthly refills ship automatically.

    Check our GLP-1 candidacy guide to see if you qualify.

    Available Medications for Memphis Residents

    Compounded Semaglutide

    $99/month

    • Same active ingredient as Wegovy
    • Weekly self-injection
    • ~15% average weight loss at 68 weeks
    • No insurance required

    Compounded Tirzepatide

    $125/month

    • Dual GLP-1/GIP receptor agonist
    • Weekly self-injection
    • ~22% average weight loss at 72 weeks
    • No insurance required

    Learn about compounded medication safety and explore our GLP-1 weight loss timeline to set realistic expectations.

    Getting Started with Trimi in Memphis

    Memphis residents with a BMI of 27+ (with a weight-related condition) or 30+ may qualify for GLP-1 treatment through Trimi. Whether you're in Midtown, Cordova, or Bartlett or anywhere in the greater Memphis area, medication ships directly to your door.

    Explore our first month on semaglutide guide, learn about managing GLP-1 side effects, or see diet tips while on semaglutide.

    Ready to Start in Memphis?

    Get compounded semaglutide delivered to any Memphis address for $99/month. No office visit, no insurance, no waiting room.

    Get Started for $99/Month

    Frequently Asked Questions: Semaglutide in Memphis

    Can I get semaglutide in Memphis without visiting a clinic?

    Yes. Trimi offers compounded semaglutide entirely through telehealth. Memphis residents complete an online health intake, receive a provider evaluation, and get medication shipped directly to their Memphis address — no in-person visit required.

    How much does semaglutide cost at Memphis weight loss clinics?

    Memphis-area weight loss clinics in neighborhoods like East Memphis, Germantown, and Collierville typically charge $300–600 per month for compounded semaglutide programs. Trimi delivers the same compounded semaglutide for $99/month.

    How fast is shipping to Memphis?

    Most Memphis residents receive their compounded semaglutide within 3–5 business days after prescription approval. Medication ships directly to your Memphis address — whether you're in Midtown, Cordova, or Bartlett.

    Is telehealth prescribing legal in Tennessee?

    Yes. Tennessee law permits licensed providers to conduct telehealth evaluations and prescribe medications including GLP-1 agonists. Trimi connects Memphis residents with licensed providers who manage care entirely online.

    Does Trimi offer tirzepatide as well as semaglutide in Memphis?

    Yes. Trimi offers both compounded semaglutide at $99/month and compounded tirzepatide at $125/month for Memphis residents. A licensed provider will help determine which medication best fits your health goals.

    What makes Memphis a high-need market for GLP-1 medications?

    Memphis has an adult obesity rate of approximately 34%, and many residents face barriers to affordable weight management. Telehealth GLP-1 programs like Trimi fill a critical gap by delivering medication directly to Memphis addresses at a fraction of clinic prices.

    Can I continue treatment if I move within the Memphis area?

    Yes. Because Trimi is a telehealth program, your care is tied to your account — not a clinic location. Whether you move within Memphis or to a nearby suburb like Olive Branch or Southaven, your treatment continues without interruption.

    Medical Disclaimer

    This article is for informational purposes only and does not constitute medical advice. Semaglutide and tirzepatide are prescription medications requiring evaluation by a licensed healthcare provider. Individual results vary. Common side effects include nausea, vomiting, diarrhea, and constipation. Not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. Shelby County Public Health Department. Community Health Assessment 2023.
    5. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: May 19, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook
    I'm on my 4th week. No side effects. 5 lb loss which seems slow to me. Food noise is much better. We shall see!

    Outcome: 5 lbs lost in 4 weeks; no side effects; food noise reduced

    Lynn SchweitzerFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Clinician-reviewed guide to semaglutide: clinical evidence, dosing considerations, side-effect management, and patient guidance. Plus how Trimi's compounded semaglutide option compares.

    Start your GLP-1 journey — from $99/mo

    Get Started